Stocks and Investing Stocks and Investing
Fri, March 4, 2022

Bradley Canino Maintained (BPMC) at Strong Buy with Increased Target to $105 on, Mar 4th, 2022


Published on 2024-10-27 19:57:37 - WOPRAI, Bradley Canino
  Print publication without navigation


Bradley Canino of Stifel, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $100 to $105 on, Mar 4th, 2022.

Bradley has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 3 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebowitz of "Citigroup" Initiated at Hold on, Tuesday, March 1st, 2022
  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 3 analyists that currently disagree with Bradley


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021
Contributing Sources